Table 2 Sex-disparate pathway enrichment. Selection of pathways significantly enriched in tumors of one sex but not the other.
From: Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer
Pathway | Female p-value | Male p-value | Cancer |
|---|---|---|---|
EIF2 Signaling | Non-significant | 2.63E-06 | HNSC |
Tight Junction Signaling | Non-significant | 1.07E-05 | HNSC |
Mitochondrial Dysfunction | Non-significant | 1.26E-05 | HNSC |
LPS/IL-1 Mediated Inhibition of RXR Function | Non-significant | 1.58E-05 | HNSC |
Activation of IRF by Cytosolic Pattern Recognition Receptors | 0.00112 | Non-significant | HNSC |
Crosstalk between Dendritic Cells and Natural Killer Cells | 0.0239 | Non-significant | HNSC |
Coagulation System | Non-significant | 0.000257 | KICH |
Acute Phase Response Signaling | Non-significant | 0.00049 | KICH |
Fatty Acid Î2-oxidation I | Non-significant | 1.78E-05 | KIRC |
Ketogenesis | Non-significant | 1.48E-04 | KIRC |
Valine Degradation I | Non-significant | 3.3E-04 | KIRC |
LXR/RXR Activation | Non-significant | 5.01E-13 | LIHC |
FXR/RXR Activation | Non-significant | 2.00E-11 | LIHC |
LPS/IL-1 Mediated Inhibition of RXR Function | Non-significant | 7.94E-08 | LIHC |
Coagulation System | Non-significant | 4.90E-07 | LIHC |
Valine Degradation I | Non-significant | 1.15E-06 | LIHC |
Sonic Hedgehog Signaling | 0.0468 | Non-significant | LIHC |
Axonal Guidance Signaling | Non-significant | 9.33E-05 | LUAD |
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | Non-significant | 1.02E-04 | LUAD |
IL-8 Signaling | Non-significant | 1.62E-04 | LUAD |
EIF2 Signaling | 9.12E-05 | Non-significant | LUAD |
